HLA-DMB: A Promising Drug Target / Biomarker (G3109)

Target Name: HLA-DMB

NCBI ID: G3109

HLA-DMB

HLA-DMB: A Promising Drug Target / Biomarker

HLA-DMB, also known as human leukemia lineage 1 demethylase gene, is a gene that encodes a protein known as HDM1. HDM1 is a key enzyme in the DNA methylation pathway, which plays a crucial role in the regulation of gene expression and cellular processes. Abnormalities in HDM1 function have been implicated in the development and progression of many diseases, including cancer. As a result, HLA-DMB has become a focus of interest in the search for new drug targets and biomarkers.

Drug Targets

HLA-DMB has been identified as a potential drug target due to its involvement in the regulation of cellular processes that are often disrupted in cancer. One of the key functions of HDM1 is its role in DNA methylation, which is critical for the regulation of gene expression. Methylation of gene promoters can inhibit the gene's ability to be expressed, which can lead to the production of proteins that promote cancer growth and the development of cancer.

In addition to its role in DNA methylation, HLA-DMB is also involved in the regulation of cellular processes that are often disrupted in cancer, such as cell division and apoptosis. Studies have shown that HDM1 is involved in the regulation of the G1/S transition, which is a critical step in the cell cycle and is often disrupted in cancer.

Biomarkers

HLA-DMB has also been identified as a potential biomarker for cancer. The ability of HDM1 to demethylate DNA has been shown to be altered in many types of cancer, which could be an indication that HDM1 is involved in the regulation of cellular processes that are critical for cancer growth. Additionally, changes in HDM1 expression have been observed in a variety of cancer types, which could be used as a potential biomarker for cancer diagnosis and prognosis.

Conclusion

HLA-DMB is a gene that has been identified as a potential drug target and biomarker for cancer. Its involvement in the regulation of DNA methylation and cellular processes makes it an attractive target for drug development. Further research is needed to fully understand the role of HLA-DMB in cancer and to develop effective treatments.

Protein Name: Major Histocompatibility Complex, Class II, DM Beta

Functions: Plays a critical role in catalyzing the release of class II-associated invariant chain peptide (CLIP) from newly synthesized MHC class II molecules and freeing the peptide binding site for acquisition of antigenic peptides. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO

The "HLA-DMB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA-DMB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets